ROCKVILLE, MD, SEPTEMBER 12, 2008— Emergent BioSolutions Inc. announced Sept. 12, 2008, that the Department of Health and Human Services has informed the company that its proposal to provide a recombinant protective antigen anthrax vaccine (rPA) is technically acceptable and within the competitive range.
Emergent BioSolutions‘ proposal was in response to HHS’ request for proposal (RFP) for development and delivery of 25 million doses of an rPA anthrax vaccine for the Strategic National Stockpile. As a next step, Emergent will begin to provide additional technical and business information in connection with the ongoing negotiation process.
Companies notified that they are within the competitive range are those that have submitted proposals that have a reasonable chance of being selected for an award based on the factors specified in HHS’ RFP.
HHS has indicated that any awards under the rPA RFP would be granted at the end of 2008, at the earliest.
“We are pleased that Emergent’s rPA vaccine candidate has advanced to this next stage and is being considered by HHS to address the government’s goal of procuring 25 million doses of a recombinant anthrax vaccine for the Strategic National Stockpile,” said Fuad El-Hibri, chairman and CEO of Emergent BioSolutions. “We believe our rPA anthrax vaccine candidate can be successfully developed and, together with BioThrax, our FDA licensed vaccine for the prevention of anthrax, can become an important component of our nation’s stockpile of medical countermeasures.”
The company expects to manufacture its rPA anthrax vaccine, as well as BioThrax, in its recently constructed manufacturing plant in Lansing, Mich.